Cite
HARVARD Citation
Gupta, R. et al. (2021). An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic. Rheumatology. pp. 977-979. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Gupta, R. et al. (2021). An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic. Rheumatology. pp. 977-979. [Online].